Dermata Therapeutics, Inc.Dermata Therapeutics, Inc.Dermata Therapeutics, Inc.

Dermata Therapeutics, Inc.

No trades
Next report date
Report period
EPS estimate
Revenue estimate
Market capitalization
‪4.58 M‬USD
−20.2893USD
‪−12.29 M‬USD
0.00USD
‪1.66 M‬
Beta (1Y)
0.79

About Dermata Therapeutics, Inc.


CEO
Gerald T. Proehl
Headquarters
San Diego
Founded
2014
Identifiers
3
ISIN US2498451168
Dermata Therapeutics, Inc. is a clinical-stage medical dermatology company that focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin diseases. Its product pipeline includes DMT310, DMT400, and DMT410. The company was founded by David F. Hale and Gerald T. Proehl on December 8, 2014 and is headquartered in San Diego, CA.
Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:
Displays a symbol's price movements over previous years to identify recurring trends.